Video Series

Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines, how they differ from previous guidelines, and the influence of these clinical guidelines on the evaluation of treatment options.

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.

Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.

Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Experts in cardiometabolic risk management examine the factors contributing to low adherence to guidelines for cardiometabolic conditions, with a specific focus on type 2 diabetes.

Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.

Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.

Experts in the field of cardiometabolic risk management analyze the link between obesity and cardiometabolic conditions, outlining challenges and proposing potential solutions.

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of targetable biomarkers.

Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.

A panel of experts examines the impact of cardiometabolic diseases in the United States, focusing on their burden, prevalence, and relationship to obesity.

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.